Keensight Capital has invested in CatSci – a contract research organisation (CRO) that supports leading pharma companies to deliver life-changing therapeutics to patients around the world.
Based in Cardiff, CatSci was formed in 2010 from a spin-out of AstraZeneca’s Catalyst Screening Facility. Its founders include CEO Dr Ross Burn, and CEO Dr Simon Tyler.
